Prince Akwasi Mensah

Array ( [id] => 6568178 [patent_doc_number] => 20020165197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-11-07 [patent_title] => 'Modulation of GSK-3beta activity and its different uses' [patent_app_type] => new [patent_app_number] => 10/078712 [patent_app_country] => US [patent_app_date] => 2002-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 9261 [patent_no_of_claims] => 55 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0165/20020165197.pdf [firstpage_image] =>[orig_patent_app_number] => 10078712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6740854 [patent_doc_number] => 20030158223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-08-21 [patent_title] => 'Pharmaceutical combination of angiotensin II antagonists and angiotensin I converting enzyme inhibitors' [patent_app_type] => new [patent_app_number] => 10/079703 [patent_app_country] => US [patent_app_date] => 2002-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2847 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0158/20030158223.pdf [firstpage_image] =>[orig_patent_app_number] => 10079703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1356582 [patent_doc_number] => 06576671 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-06-10 [patent_title] => 'Aminotetralin derivatives for the therapy of cardiovascular diseases' [patent_app_type] => B1 [patent_app_number] => 10/009352 [patent_app_country] => US [patent_app_date] => 2002-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3788 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/576/06576671.pdf [firstpage_image] =>[orig_patent_app_number] => 10009352 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6721380 [patent_doc_number] => 20030055070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-03-20 [patent_title] => 'Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of selective serotonin reuptake inhibitor (SSR) induced sexual dysfunction' [patent_app_type] => new [patent_app_number] => 10/079991 [patent_app_country] => US [patent_app_date] => 2002-02-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7205 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0055/20030055070.pdf [firstpage_image] =>[orig_patent_app_number] => 10079991 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1341383 [patent_doc_number] => 06589992 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2003-07-08 [patent_title] => 'Inhibiting collagen-induced platelet aggregation' [patent_app_type] => B2 [patent_app_number] => 10/077514 [patent_app_country] => US [patent_app_date] => 2002-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 40 [patent_no_of_words] => 10489 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/589/06589992.pdf [firstpage_image] =>[orig_patent_app_number] => 10077514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6693109 [patent_doc_number] => 20030040541 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-02-27 [patent_title] => 'Use of bismuth subgallate in inhibition of production of nitric oxide synthase' [patent_app_type] => new [patent_app_number] => 10/075040 [patent_app_country] => US [patent_app_date] => 2002-02-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 2583 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0040/20030040541.pdf [firstpage_image] =>[orig_patent_app_number] => 10075040 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6792613 [patent_doc_number] => 20030087957 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2003-05-08 [patent_title] => 'Alpha-aryl-N-alkylnitrones and pharmaceutical compositions containing the same' [patent_app_type] => new [patent_app_number] => 10/074595 [patent_app_country] => US [patent_app_date] => 2002-02-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 22776 [patent_no_of_claims] => 61 [patent_no_of_ind_claims] => 18 [patent_words_short_claim] => 5 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0087/20030087957.pdf [firstpage_image] =>[orig_patent_app_number] => 10074595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1062538 [patent_doc_number] => 06849281 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2005-02-01 [patent_title] => 'Food product suitable for reducing low density lipoprotein cholesterol levels' [patent_app_type] => utility [patent_app_number] => 10/072580 [patent_app_country] => US [patent_app_date] => 2002-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6405 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/849/06849281.pdf [firstpage_image] =>[orig_patent_app_number] => 10072580 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1265217 [patent_doc_number] => 06660761 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2003-12-09 [patent_title] => 'Method of treatment for fungal infections with a synergistic formulation of antifungal agents' [patent_app_type] => B2 [patent_app_number] => 10/066802 [patent_app_country] => US [patent_app_date] => 2002-02-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4184 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/660/06660761.pdf [firstpage_image] =>[orig_patent_app_number] => 10066802 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1034581 [patent_doc_number] => 06875792 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2005-04-05 [patent_title] => 'Dosage form of L-Methionine S-Sulfoximine' [patent_app_type] => utility [patent_app_number] => 10/060099 [patent_app_country] => US [patent_app_date] => 2002-01-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 5436 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/875/06875792.pdf [firstpage_image] =>[orig_patent_app_number] => 10060099 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 716017 [patent_doc_number] => 07053092 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2006-05-30 [patent_title] => '5-HT1a receptor subtype agonist' [patent_app_type] => utility [patent_app_number] => 10/055915 [patent_app_country] => US [patent_app_date] => 2002-01-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4706 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 73 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/07/053/07053092.pdf [firstpage_image] =>[orig_patent_app_number] => 10055915 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1325766 [patent_doc_number] => 06602909 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-08-05 [patent_title] => 'Selected essential amino acid supplementation of dietary proteins to lower urinary urea and peak glucose levels' [patent_app_type] => B1 [patent_app_number] => 10/053265 [patent_app_country] => US [patent_app_date] => 2002-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 886 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/602/06602909.pdf [firstpage_image] =>[orig_patent_app_number] => 10053265 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1350879 [patent_doc_number] => RE038115 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2003-05-06 [patent_title] => 'Dextromethorphan and an oxidase inhibitor for treating intractable conditions' [patent_app_type] => E1 [patent_app_number] => 10/052698 [patent_app_country] => US [patent_app_date] => 2002-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 9140 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/RE/038/RE038115.pdf [firstpage_image] =>[orig_patent_app_number] => 10052698 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 1417247 [patent_doc_number] => 06512011 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2003-01-28 [patent_title] => 'Bupropion to treat herpes viral diseases' [patent_app_type] => B1 [patent_app_number] => 09/787024 [patent_app_country] => US [patent_app_date] => 2002-01-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3179 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] => patents/06/512/06512011.pdf [firstpage_image] =>[orig_patent_app_number] => 09787024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5788646 [patent_doc_number] => 20020161002 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-31 [patent_title] => 'Use of catecholamine reuptake inhibitors to enhance memory' [patent_app_type] => new [patent_app_number] => 10/039229 [patent_app_country] => US [patent_app_date] => 2002-01-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 13030 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0161/20020161002.pdf [firstpage_image] =>[orig_patent_app_number] => 10039229 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6177932 [patent_doc_number] => 20020156067 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-10-24 [patent_title] => 'New drug combinations' [patent_app_type] => new [patent_app_number] => 10/035100 [patent_app_country] => US [patent_app_date] => 2001-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5431 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 40 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0156/20020156067.pdf [firstpage_image] =>[orig_patent_app_number] => 10035100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 6278719 [patent_doc_number] => 20020107248 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2002-08-08 [patent_title] => 'Method for treating patients with neoplasia by administering substituted sulfonyl indenyl acetic and propionic acids and esters thereof' [patent_app_type] => new [patent_app_number] => 10/040601 [patent_app_country] => US [patent_app_date] => 2001-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12020 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0107/20020107248.pdf [firstpage_image] =>[orig_patent_app_number] => 10040601 [rel_patent_id] =>[rel_patent_doc_number] =>)